Orion Pharma Limited announcements
187 Dhaka Stock Exchange announcements for Orion Pharma Limited (ORIONPHARM) since 2013: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2021 (12).
- Resumption after record date
Trading of the shares of the Company will resume on 30.11.2021 after record date.
- Suspension for Record date
Trading of the shares of the Company will remain suspended on record date i.e., 29.11.2021 for EGM and AGM.
- Spot for EGM & AGM
Trading of the shares of the Company will be allowed only in the Spot Market and Block transactions will also be settled as per Spot settlement cycle with cum benefit from 25.11.2021 to 28.11.2021. Trading of the shares of the Company will remain suspended on record date i.e., 29.11.2021 for EGM and AGM.
- Q1 Financials
(Q1 Un-audited): Consolidated EPS was Tk. 0.30 for July-September 2021 as against Tk. 0.82 for July-September 2020; Consolidated NOCFPS was Tk. 1.52 for July-September 2021 as against Tk. 1.46 for July-September 2020. Consolidated NAV per share (including revaluation surplus) was Tk. 80.55 as on September 30, 2021 and Tk. 79.76 as on June 30, 2021. Consolidated NAV per share (excluding revaluation surplus) was Tk. 72.59 as on September 30, 2021 and Tk. 71.79 as on June 30, 2021.
- Q1 Financials (additional Information)
The EPS of Q1 (July '21 to September '21) has significantly decreased compared to the EPS of same period of last year due to no revenue generation from the two of the subsidiary companies namely Orion Power Meghnaghat Limited. and Dutch Bangla power & Associates Ltd. as their contract period has expired. However, the contract renewal with BPDB of the above two subsidiaries is under process.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 14, 2021 at 4:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2021.
- Dividend Declaration and EGM for Related Party Transaction
(Continuation news of ORIONPHARM): The Company has reported Consolidated EPS of Tk. 4.01, Consolidated NAV per share (Including Revaluation Surplus) of Tk. 79.76, Consolidated NAV per share (Excluding Revaluation Surplus) of Tk. 71.79 and Consolidated NOCFPS of Tk. 11.07 for the year ended on June 30, 2021 as against Tk. 2.84, Tk. 76.77, Tk. 68.69 and Tk. 8.04 respectively for the same period of the previous year. (end)
The first part of this announcement is missing from the archive. - Price Limit Open
There will be no price limit on the trading of the shares of the Company today (09.11.2021) following its corporate declaration.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 08, 2021 at 4:00 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2021.
- Query Response
In response to a DSE query dated October 04, 2021, the Company has informed that there is no undisclosed price sensitive information of the Company for recent unusual price hike and increase in volume of shares.
- A preliminary proposal made to RDIF for Covid-19 vaccine
(Continuation news of ORIONPHARM): They also informed that this is just a preliminary proposal as a normal and regular business communication of the Company made to RDIF from their end like other Pharmaceutical Companies of the country. But the success will of course depend on the final decision of RDIF and subsequent approval of Govt. of Bangladesh. (end)
The first part of this announcement is missing from the archive. - Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 30, 2021 at 5:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2020.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.